Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology.
In: Molecular Neurodegeneration, Jg. 19 (2024-01-07), Heft 1, S. 1-14
Online
academicJournal
Zugriff:
Background: Antibody-based immunoassays have enabled quantification of very low concentrations of phosphorylated tau (p-tau) protein forms in cerebrospinal fluid (CSF), aiding in the diagnosis of AD. Mass spectrometry enables absolute quantification of multiple p-tau variants within a single run. The goal of this study was to compare the performance of mass spectrometry assessments of p-tau181, p-tau217 and p-tau231 with established immunoassay techniques. Methods: We measured p-tau181, p-tau217 and p-tau231 concentrations in CSF from 173 participants from the TRIAD cohort and 394 participants from the BioFINDER-2 cohort using both mass spectrometry and immunoassay methods. All subjects were clinically evaluated by dementia specialists and had amyloid-PET and tau-PET assessments. Bland–Altman analyses evaluated the agreement between immunoassay and mass spectrometry p-tau181, p-tau217 and p-tau231. P-tau associations with amyloid-PET and tau-PET uptake were also compared. Receiver Operating Characteristic (ROC) analyses compared the performance of mass spectrometry and immunoassays p-tau concentrations to identify amyloid-PET positivity. Results: Mass spectrometry and immunoassays of p-tau217 were highly comparable in terms of diagnostic performance, between-group effect sizes and associations with PET biomarkers. In contrast, p-tau181 and p-tau231 concentrations measured using antibody-free mass spectrometry had lower performance compared with immunoassays. Conclusions: Our results suggest that while similar overall, immunoassay-based p-tau biomarkers are slightly superior to antibody-free mass spectrometry-based p-tau biomarkers. Future work is needed to determine whether the potential to evaluate multiple biomarkers within a single run offsets the slightly lower performance of antibody-free mass spectrometry-based p-tau quantification. [ABSTRACT FROM AUTHOR]
Titel: |
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology.
|
---|---|
Autor/in / Beteiligte Person: | Therriault, Joseph ; Woo, Marcel S. ; Salvadó, Gemma ; Gobom, Johan ; Karikari, Thomas K. ; Janelidze, Shorena ; Servaes, Stijn ; Rahmouni, Nesrine ; Tissot, Cécile ; Ashton, Nicholas J. ; Benedet, Andréa Lessa ; Montoliu-Gaya, Laia ; Macedo, Arthur C. ; Lussier, Firoza Z. ; Stevenson, Jenna ; Vitali, Paolo ; Friese, Manuel A. ; Massarweh, Gassan ; Soucy, Jean-Paul ; Pascoal, Tharick A. |
Link: | |
Zeitschrift: | Molecular Neurodegeneration, Jg. 19 (2024-01-07), Heft 1, S. 1-14 |
Veröffentlichung: | 2024 |
Medientyp: | academicJournal |
ISSN: | 1750-1326 (print) |
DOI: | 10.1186/s13024-023-00689-2 |
Schlagwort: |
|
Sonstiges: |
|